AZD-5991

• CAT Number: I019688
• CAS Number: 2143061-81-6
• Molecular Formula: C₃₅H₃₄ClN₅O₃S₂
• Molecular Weight: 672.26
• Purity: ≥95%
• Target: Bcl-2 Family
• IUPAC Name: 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(36),4(38),6,11,14,16,18,20,23,29(37),30,32,34-tridecaene-23-carboxylic acid
• InChI: 1S/C35H34ClN5O3S2/c1-20-31-29(38-40(20)3)19-45-17-22-15-23(41(4)37-22)18-46-24-14-21-8-5-6-9-25(21)30(16-24)44-13-7-10-26-27-11-12-28(36)32(31)33(27)39(2)34(26)35(42)43/h5-6,8-9,11-12,14-16H,7,10,13,17-19H2,1-4H3,(H,42,43)
• InChIKey: KBQCEQAXHPIRTF-UHFFFAOYSA-N
• SMILES: CC1=C2C(=NN1C)CSCC3=NN(C(=C3)CSC4=CC5=CC=CC=C5C(=C4)OCCCC6=C(N(C7=C6C=CC(=C27)Cl)C)C(=O)O)C

AZD-5991 (CAT: I019688) is a small-molecule inhibitor that targets the anti-apoptotic protein Mcl-1 (myeloid cell leukemia 1). Mcl-1 is a member of the Bcl-2 protein family and plays a critical role in promoting cancer cell survival by preventing apoptosis. AZD-5991 selectively binds to Mcl-1, displacing the pro-apoptotic proteins Bak and Bim, thereby promoting apoptosis in cancer cells. This inhibition of the Mcl-1 function has shown promising anti-cancer effects in preclinical studies, including both solid tumors and hematological malignancies. AZD-5991 is being investigated as a potential therapeutic option for cancer treatment, particularly in cases where elevated Mcl-1 levels contribute to treatment resistance. Clinical trials are underway to evaluate its safety and efficacy in cancer patients.

Reference

[1]. Tron AE, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018 Dec 17;9(1):5341.